Home > Insider Trading > Filing (0001144204-15-011504)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1604072	Ii Capital Ventech	47 Avenue De L'Opera Paris Cedex 07 I0 75002		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-02-19	506,563	$0.00	506,563	No	4	C	Direct
Common Stock	Acquisiton	2015-02-19	142,218	$0.00	648,781	No	4	C	Direct
Common Stock	Acquisiton	2015-02-19	501,405	$0.00	1,150,186	No	4	C	Direct
Common Stock	Acquisiton	2015-02-19	241,270	$4.20	1,391,456	No	4	C	Direct
Common Stock	Acquisiton	2015-02-19	102,777	$6.00	1,494,233	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2015-02-19	11,801	$0.00	11,801	$0.00
Common Stock	Series C Preferred Stock	Disposition	2015-02-19	17,363	$0.00	17,363	$0.00
Common Stock	Series D Preferred Stock	Disposition	2015-02-19	140,685	$0.00	140,685	$0.00
Common Stock	Convertible Promissory Note	Acquisiton	2015-02-19	0	$1,013,334.00	241,270	$4.20
Common Stock	Convertible Promissory Note	Disposition	2015-02-19	0	$0.00	241,270	$4.20

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
		No	4	C	Direct
		No	4	C	Direct
		No	4	C	Direct
2015-02-19	2015-06-06	No	4	P	Direct
2015-02-19	2015-06-06	No	4	C	Direct

Footnotes

Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 10.94-for-one basis, and had no expiration date.
Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 9.60-for-one basis, and had no expiration date.
Upon closing of the Issuer's initial public offering, each share of Series D Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 10.96-for-one basis, and had no expiration date.